Kingdom Hearts 3D At 650,000 In The West; Sleeping Dogs At 1.5 Million

This article is over 12 years old and may contain outdated information

Recommended Videos

As reported last night, Square Enix reported a $68 million loss for the first half of their ongoing fiscal year, from April to September. Square have cited sluggish sales of a “major HD title” as one of the primary causes for their performance.

 

While Square Enix didn’t specify just which game it was that underperformed, they did provide shipment figures for their major recent releases up until September. Take a look at the numbers below:

 

(PSP) Final Fantasy III – 80,000 (JPN)

 

(3DS) Heroes of Ruin – 130,000 (US/EU)

(3DS) Theatrhythm: Final Fantasy – 150,000 (US/EU – JPN not included)

(3DS) Kingdom Hearts 3D – 650,000 (US/EU – JPN not included)

(3DS) Dragon Quest Monsters: Terry’s Wonderland 3D – 900,000 (JPN)

 

(Wii) Dragon Quest X – 700,000 (JPN)

(PC/360/PS3) Sleeping Dogs – 1.51 million (US/EU/JPN)

 

650,000 copies of Kingdom Hearts 3D shipped to the U.S. and Europe should put the title somewhere near the 1 million mark worldwide. As of May 2012, Kingdom Hearts 3D had sold 312,000 copies in Japan. We also know that the game sold over 200,000 copies in North America during the month of its launch.

 

The Sleeping Dogs number is interesting, too. Square Enix’s report describes Sleeping Dogs as a “highly-acclaimed new IP” and one with top-class sales among new IP titles in North America during the last one year.


Siliconera is supported by our audience. When you purchase through links on our site, we may earn a small affiliate commission. Learn more about our Affiliate Policy
Author
Image of Ishaan Sahdev
Ishaan Sahdev
Ishaan specializes in game design/sales analysis. He's the former managing editor of Siliconera and wrote the book "The Legend of Zelda - A Complete Development History". He also used to moonlight as a professional manga editor. These days, his day job has nothing to do with games, but the two inform each other nonetheless.